Go Pro
NASDAQ:BDTX

Black Diamond Therapeutics Q1 2026 Earnings Report

Black Diamond Therapeutics logo
$1.74 +0.05 (+2.66%)
Closing price 04:00 PM Eastern
Extended Trading
$1.73 -0.01 (-0.35%)
As of 04:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Black Diamond Therapeutics EPS Results

Actual EPS
-$0.16
Consensus EPS
-$0.18
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Black Diamond Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$25.00 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Black Diamond Therapeutics Announcement Details

Quarter
Q1 2026
Time
After Market Closes
Conference Call Date
Thursday, May 7, 2026
Conference Call Time
7:00AM ET

Upcoming Earnings

Black Diamond Therapeutics' Q2 2026 earnings is estimated for Thursday, August 6, 2026, based on past reporting schedules

Black Diamond Therapeutics Earnings Headlines

Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.tc pixel
Black Diamond Therapeutics, Inc.
See More Black Diamond Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Black Diamond Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Black Diamond Therapeutics and other key companies, straight to your email.

About Black Diamond Therapeutics

Black Diamond Therapeutics (NASDAQ:BDTX) is a precision oncology company focused on the discovery and development of small-molecule therapies that selectively target oncogenic proteins bearing tumor-driving mutations. Leveraging its proprietary Genetic Defined Allosteric (GDA) therapeutic platform, the company aims to identify unique allosteric binding sites in mutant proteins and engineer highly selective inhibitors. Headquartered in Cambridge, Massachusetts, Black Diamond applies structure-based drug design and molecular modeling to advance personalized cancer treatments.

The company’s development pipeline includes lead candidate BDTX-189, an allosteric inhibitor of mutant HER2, as well as programs directed at clinically relevant EGFR and KRAS mutations. Black Diamond’s approach seeks to overcome resistance mechanisms that often limit the efficacy of existing therapies by focusing on mutation-specific vulnerabilities. Early-stage clinical trials for BDTX-189 are evaluating safety, pharmacokinetics, and anti-tumor activity in patients whose tumors harbor HER2 alterations.

Founded in 2019 and listed on the Nasdaq under the ticker BDTX, Black Diamond Therapeutics combines scientific expertise with experience drawn from leading biopharmaceutical organizations. The company collaborates with academic centers and research institutions to advance its pipeline and is committed to delivering next-generation precision medicines to oncology patients worldwide.

View Black Diamond Therapeutics Profile